Davide Rossi
About
Prof. Rossi serves as an Associate Professor at the Faculty of Biomedicine, Università della Svizzera italiana. He is also the Head of the Laboratory of Experimental Hematology at the Institute of Oncology Research, Deputy Head at the Clinic of Hematology of the Oncology Institute of Southern Switzerland, and oversees the Lymphoid Tumors Program there. Prof. Rossi has earned national and international recognition as a scientist, particularly in the fields of lymphoma and chronic lymphocytic leukemia, as evidenced by his extensive publication record. He has received grants from prestigious organizations such as the European Research Council, the Swiss National Science Foundation, the Swiss Cancer League, the Leukemia & Lymphoma Society, and various other national and international bodies. He serves as a member of the Scientific Committee of the Leukemia Project Group within the Swiss Group for Clinical Cancer Research (SAKK). Additionally, he acts as the Principal Investigator for institutional and national clinical trials focused on chronic lymphocytic leukemia and lymphoma. Prof. Rossi has contributed to the 5th Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. He is frequently invited to speak at international meetings and serves as a member of the International Workshop on Chronic Lymphocytic Leukemia. Additionally, he is involved in the Organizing and Program Committees of major events such as the International Conference on Malignant Lymphoma, the Congress of the European Hematology Association, and the European Society of Medical Oncology Congress. Prof. Rossi actively engages in a broad network of national and international collaborations, as evidenced by numerous collaboration-driven publications. In recognition of his research contributions in the field of lymphomas, he has received prestigious awards such as the "Sivia Fiocco" prize from the Italian National Academy of Science, the "Ellermann" prize from the Swiss Society of Hematology, and the Robert Wenner Award from the Swiss Cancer League. Prof. Rossi focuses on the molecular pathogenesis of mature B-cell tumors, making significant contributions to the field. His key achievements include: (i) discovering several driver mutations in chronic lymphocytic leukemia and establishing their role as prognostic biomarkers; (ii) elucidating the molecular underpinnings of high-risk chronic lymphocytic leukemia, including refractory and transformed forms of the disease; (iii) developing prognostic scores for chronic lymphocytic leukemia; (iv) identifying driver genes and genetic subtypes of marginal zone lymphoma that aid in disease classification; and (v) advancing the clinical application of circulating tumor DNA in classic Hodgkin lymphoma. Many of his discoveries have been integrated into the 5th Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues. Overall, Prof. Rossi is author of 365 peer reviewed publications (citations: 34272; h-index: 91).
Work
Publications
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival.
Published by
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Summary
journal-article
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.
Published by
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Summary
journal-article